A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1
Por:
Krebs, M, Brunsvig, P, Helland, A, Vinolas, N, Aix, S, Carcereny, E, Gomez, MD, Perez, JMT, Arriola, E, Campelo, RG, Spicer, J, Thompson, J, Granados, ALO, Holt, R, Smethurst, D, Lorens, J, Shoaib, M, Siddiqui, A, Schoelermann, J, Lorens, K, Schmidt, E, Chisamore, MJ and Felip, E
Publicada:
1 oct 2019
Resumen:
Filiaciones:
Krebs, M:
Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
Univ Manchester, Manchester, Lancs, England
Brunsvig, P:
Oslo Univ Hosp, Oslo, Norway
Helland, A:
Oslo Univ Hosp, Inst Canc Res, Norwegian Radium Hosp, Oslo, Norway
Vinolas, N:
Hosp Clin Barcelona, Barcelona, Spain
Aix, S:
Hosp 12 Octubre Carretera Andalucia, Madrid, Spain
:
Catalan Inst Oncol Badalona, Med Oncol, Badalona, Spain
Hosp Badalona Germans Trias & Pujol, Badalona, Spain
B Argo, Badalona, Spain
Gomez, MD:
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
Perez, JMT:
Hosp Virgen de la Victoria, Malaga, Spain
Arriola, E:
Hosp Mar, Oncol, Barcelona, Spain
Campelo, RG:
Univ Hosp A Coruna Xxiac Sergas, Med Oncol Serv, La Coruna, Spain
Spicer, J:
KingS Coll London, Guys Hosp, London, England
Thompson, J:
Med Coll Wisconsin, Affiliated Hosp, Menomonee Falls, WI USA
Granados, ALO:
Complejo Hosp Jaen, Med Oncol, Jaen, Spain
Holt, R:
Bergenbio Asa, Bergen, Norway
Smethurst, D:
Bergenbio Asa, Bergen, Norway
Lorens, J:
Bergenbio Asa, Bergen, Norway
Shoaib, M:
Bergenbio Asa, Bergen, Norway
Siddiqui, A:
Bergenbio Asa, Bergen, Norway
Schoelermann, J:
Bergenbio Asa, Bergen, Norway
Lorens, K:
Bergenbio Asa, Bergen, Norway
Schmidt, E:
Merck & Co Inc, Kenilworth, NJ USA
Chisamore, MJ:
Merck & Co Inc, Rahway, NJ 07065 USA
Felip, E:
Vall dHebron Univ Hosp, Barcelona, Spain
Bronze
|